SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MedImmune
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Shlepper who wrote (62)7/19/1997 2:50:00 AM
From: Pseudo Biologist   of 416
 
Hi Shep, I got some info on Osiris, which I will post later when I'm fully awake. Perhaps it will juggle your mind a bit. Celgene rings a bell; I'll take a look.

I've studied TCLN a bit. It is a very intriguing story that's been going one for quite a long time. Perhaps worth some nibbling for the reasons you state. I still have to gather the time and energy to figure out their recent financing. At $4 it has a market cap of ~$130 or so million, not cheap if you only look at their First World clinical pipeline. I say this because they are also testing a very interesting approach (which they call TNT) in China and (maybe?) in Mexico. Their research also looks interesting, but won't go anywhere if they cannot get more support either from corporate partners or from success in the clinic of their Lym-1 monoclonal. What's your take?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News